Whilst several studies have used magnetic resonance imaging (MRI) to attempt to non-invasively characterize the IDH1 mutation in gliomas ([4, 7–12], the potential for positron emission tomography (PET) as a complementary metabolic imaging tool, is a growing field [13, 14]. The gene discussed is IDH1; the disease is central nervous system cancer.